> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-209/
- Published: 2019-09-10T12:00:00.000Z
- Updated: 2026-09-15T01:49:03.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144967

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

**Enprani Co.**, Seoul, South Korea (8/15): FDA inspected the firm in March and cited significant GMP violations for finished pharmaceuticals. For example, The company failed to have, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications. Enprani also failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/enprani-co-ltd-580548-08152019?ref=fdaweb.com).

**Hangzhou Badi Daily Use Chemical** Huzhou City, China (8/29): FDA inspected the firm in March and cited significant GMP violations for finished pharmaceuticals. For example, the firm failed to conduct at least one test to verify the identity of each component of a drug product. The company also failed to establish adequate written procedures for production and process control designed to assure that the drug products manufactured have the identity, strength, quality, and purity they purport or are represented to possess. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hangzhou-badi-daily-use-chemical-company-580819-08292019?ref=fdaweb.com).